1ST Biotherapeutics raises $7.6M in follow-on funding led by SK Biopharmaceuticals and Murex Partners to advance cancer drug trials.
Amount Raised
$7.6 Million
Round Type
Venture
Investors
Description
1ST Biotherapeutics closed a $7.6 million follow-on funding round, bringing cumulative funding to approximately $89 million. The round was led by strategic investor SK Biopharmaceuticals and includes participation from Murex Partners. The capital will support clinical development of FB849, an HPK1 inhibitor currently in Phase 1/2 trials, and research on follow-on pipeline candidates. The company plans to initiate a Phase 2 combination trial with Merck's Keytruda in Q1 2027 and is targeting an IPO in 2027.
Quick answer
1ST Biotherapeutics raised $7.6 Million in a funding round, dated September 1, 2026. Investors: Murex Partners and SK Biopharmaceuticals.
- How much did 1ST Biotherapeutics raise?
- 1ST Biotherapeutics raised $7.6 Million in a funding round on September 1, 2026.
- Who invested in 1ST Biotherapeutics?
- Murex Partners and SK Biopharmaceuticals are named as investors in this round.
- What does 1ST Biotherapeutics do?
- 1ST Biotherapeutics is a biopharmaceutical company developing cancer immunotherapy treatments, with a lead pipeline asset FB849, an HPK1 inhibitor currently in Phase 1/2 trials.
- Where is 1ST Biotherapeutics based and how big is it?
- Fundz records about 11 employees.
- Who are the decision-makers at 1ST Biotherapeutics?
- Fundz holds 2 contacts at 1ST Biotherapeutics, including the Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as 1ST Biotherapeutics that raised within 45 days of this round, from Fundz verified event records.
- Acta Pharmaceuticals raised $24M (Seed) on October 15, 2026.
- Os Therapies raised $7.2M on October 15, 2026.
- Ensho Therapeutics raised $7.3M on October 2, 2026.
- Breye Therapeutics raised $77M (Series A) on September 29, 2026.
- Orvida Pharma raised an undisclosed amount on September 15, 2026.
- Clene Nanomedicine raised $4M (Post-IPO Equity) on September 15, 2026.
Who to call at 1ST Biotherapeutics, and when
A new round usually means 1ST Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day 1ST Biotherapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at 1ST Biotherapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at 1ST Biotherapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment 1ST Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
1ST Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.